Clinical trials: Tislelizumab
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
The goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck…
- Trial name
- NCT07776340
- Testing
- Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Pancreatic Cancer
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a…
- Trial name
- NCT07671339
- Testing
- ELI-002 7P, Tislelizumab, mFOLFIRINOX
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma (DLBCL)
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
This is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab…
- Trial name
- Pola-ZRCHP (NCT07608978)
- Testing
- POLA-R-CHP+Zanubrutinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
MCRC
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
This is a multicenter, open-label, prospective, randomized controlled Phase II clinical study. All eligible subjects will be randomly assigned in a 1:1 ratio to either the triple therapy group or the double therapy group.
- Trial name
- THYMI (NCT06829355)
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), Regorafenib (BAY 73-4506), Tislelizumab (BGB-A317)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Beijing Friendship Hospital
Locally Advanced Rectal Cancer
Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score
This is a prospective, one arm phase II study aimed to observe the efficacy and safety of tislelizumab combined with fruquintinib in treatment of patients with pMMR / MSS locally advanced rectal cancer with high immune score.
- Trial name
- NCT04989855
- Testing
- Fruquintinib plus Tislelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
This study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line Tislelizumab treatment in advanced NSCLC.
- Trial name
- REALM-Post (NCT06962449)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
The goal of this clinical trial is to explore the efficacy and safety of denosumab in combination with tislelizumab and chemotherapy in the second-line treatment of immuno-experienced patients with EGFR/ALK/ROS1-negative advanced…
- Trial name
- NCT06749886
- Testing
- Denosumab, tislelizumab, Docetaxel
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent…
- Conditions
- Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- RETICULA-NPC (NCT04921995)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Large B-cell Lymphoma
LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
This study evaluates a personalized treatment strategy for patients with large B-cell lymphoma (LBCL) whose disease has relapsed or not responded after CD19 CAR-T cell therapy.
- Trial name
- NCT07602322
- Testing
- LME-Guided Combination Therapy Regimen, Glofitamab Monotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
Although immunotherapy-based therapies (including targeted-immunotherapy or dual-immunotherapy protocols) have become the first-line standard treatment for advanced hepatocellular carcinoma (HCC), there remains a lack of…
- Trial name
- NCT07501351
- Testing
- Intensified Therapy, Conversion Therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Biliary Tract Cancer
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract…
- Trial name
- NCT05254847
- Testing
- Capecitabine combined with lenvatinib and tislelizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Lung Cancer (Locally Advanced or Metastatic)
The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer
To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery
- Trial name
- NCT07638878
- Testing
- tislelizumab in combination with nab-paclitaxel and platinum chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Medical University
Advanced Solid Tumors
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This was an open-label, multicenter, non-randomized Phase 1b clinical trial for participants with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous non-small cell…
- Trial name
- NCT03666143
- Testing
- Sitravatinib, Tislelizumab
- Where
- 19 sites in Australia, China
- Volunteers
- 216 people
- Sponsor
- BeiGene
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
- Trial name
- NCT06838208
- Testing
- Tislelizumab, Carboplatin /Cisplatin, Etoposide
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Anhui Provincial Cancer Hospital
Hepatocellular Carcinoma
Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib as first-line treatment in patients with advanced HCC.
- Trial name
- CASTLE-10 (NCT05897268)
- Testing
- Cryoablation, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Liver Neoplasms
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Background: Ablation is important radical treatment in hepatocellular carcinoma (HCC). However, the 5-year recurrence rate of HCC after ablation is up to 80%.
- Trial name
- NCT06059885
- Testing
- Tislelizumab plus tyrosine kinase inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
Urinary Bladder Neoplasms
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Nowadays, Immune Checkpoint Inhibitor (ICI) has become one of the new drugs for the treatment of advanced uroepithelial carcinoma.
- Trial name
- CBPTMI (NCT05445648)
- Testing
- Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Lung Cancer (NSCLC)
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
This is a single-arm study evaluating the efficacy and safety of Stapokibart Injection in combination with Tislelizumab Injection in patients with driver gene-negative NSCLC who have failed prior PD-1/PD-L1 inhibitor therapy.
- Trial name
- NCT06883552
- Testing
- Tislelizumab Injection
- Volunteers
- 21 people
- Sponsor
- Sichuan University
Laryngeal Cancer, Hypopharynx Cancer
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of "tislelizumab combined with chemotherapy followed by…
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- NCT06554028
- Testing
- chemotherapy TP regimen combined with Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma With PVTT
HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)
To estimate the safety and efficacy of hepatic artery infusion chemotherapy (HAIC) combine Tislelizumab and Lenvatinib (HAI-TIS-LEN) in the Treatment of hepatocellular carcinoma (HCC) with type IV(Vp4) portal vein tumor thrombus…
- Trial name
- HAI-TL (NCT06210334)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Li Xiao Wei